Sharemaestro company-news research for Zai Lab Ltd (ZLAB), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
NASDAQ
United States
Insufficient evidence
Company news sentiment
Latest ZLAB news and sentiment
Zai Lab Ltd
Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.
Current company news
No current company-news score
No company-specific headline in the last 30 days currently passes the date and relevance checks. The dash means no score; it is not a neutral observation.
Observed headline tone50/100
→
Published 30-day score50/100
Latest source headline
Form 4 Zai Lab Ltd For: Oct 01 Filed by: Chen Yajing
StreetInsider · 05 Oct 2026 21:02
Older, less relevant and less reliable stories count for less. Confidence is shown separately.
Available information
6 current stories are mapped specifically to ZLAB.
Why there is no score
The stories agree, but freshness-weighted evidence is only 0.000.
Confidence is 0/100, below the threshold for a firm score.
—/100
News scoreNo qualifying directional evidence
0/100
Confidencethin evidence
0%/100
Company news6 company stories
100/100
Story agreement0/100 difference
News history
Daily score and story count over 30 days
15 Sep30 Sep14 Oct
News scoreStory count50 baseline
Confidence
How reliable the score is
Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.
Amount of evidence0
0.0 after freshness weightingSource breadth0
0 independent publishersCompany relevance0
share tied directly to this companyFreshness18
recency-weighted evidenceAgreement100
how closely stories agreePublisher mix0
less reliance on one publisherPrice and news history
Weekly price and news-score history
No sufficiently fresh, directly relevant company news is available for a price comparison.
26 completed price weeks16 comparable news-score weeks
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
17 Apr14 Jul09 Oct
Weekly close, indexedSentiment score
WeekNews scoreCloseWeekly move
09 Oct 202650USD 24.99+2.7%
02 Oct 202650USD 24.33-2.6%
25 Sep 202650USD 24.98-2.8%
18 Sep 202650USD 25.7+6.5%
11 Sep 202651USD 24.14-8.0%
04 Sep 202653USD 26.23+0.6%
28 Aug 202656USD 26.08+0.3%
21 Aug 202657USD 26.01+0.4%
Insufficient evidence
News subjects
What is shaping the score
Market update503 stories · 50%
Earnings551 stories · 17%
Deals and strategy501 stories · 17%
Analyst action501 stories · 17%
Source mix
Where the evidence comes from
Simply Wall Street502 stories · 33%
AD HOC NEWS551 stories · 17%
StreetInsider501 stories · 17%
Simply Wall St.501 stories · 17%
The Globe and Mail501 stories · 17%
Recurring subjects
Subjects appearing most often
Life Sciences5Earnings5Financial Markets4Finance2Shareholder1Share Price1Oncology1Future Cash Flows1Clinical Trials1Balance Sheet1
Earlier readings
How the score has changed
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
25 Jun50 neutral14 Oct 17:06
ConstructiveBalanced or withheldCautious
Changes in the stored score
Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.
| Observed | Score | Move | Confidence | Stories | Status |
|---|---|---|---|---|---|
| 14 Oct 17:06 | 50 | +0 | 0/100 (0) | 6 (-1) | Insufficient |
| 05 Oct 23:59 | 50 | +0 | 0/100 (0) | 7 (+1) | Insufficient |
| 04 Oct 23:59 | 50 | +0 | 0/100 (0) | 6 (+1) | Insufficient |
| 03 Oct 23:59 | 50 | +0 | 0/100 (0) | 5 (+1) | Insufficient |
| 01 Oct 23:59 | 50 | +0 | 0/100 (-15) | 4 (-2) | Insufficient |
| 23 Sep 23:59 | 50 | +0 | 15/100 (0) | 6 (0) | Provisional |
| 19 Sep 23:59 | 50 | -2 | 15/100 (-6) | 6 (-21) | Provisional |
| 06 Sep 23:59 | 52 | -3 | 21/100 (-9) | 27 (-10) | Provisional |
Evidence behind the direction
What drives this reading?
Shares of weighted directional evidence in 6 retained current headlines. These weights already account for freshness, relevance and publisher limits; they are not additive points of the published score.
No directional evidence to attribute yet
Company news can still be read below. Influence bars appear when a current story qualifies for the directional score.
Source headlines
The news behind the score
Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.
—Unscored
Deals and strategyNot used in direction
Form 4 Zai Lab Ltd For: Oct 01 Filed by: Chen Yajing
This Form 4 filing indicates changes in beneficial ownership for Chen Yajing, Chief Financial Officer of Zai Lab Ltd. The filing details the acquisition of 920 American Depositary Shares (ADSs) upon vesting of Restricted Share Units (RSUs) and the disposal of 315 ADSs withheld to cover ta…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
This Form 4 filing indicates changes in beneficial ownership for Chen Yajing, Chief Financial Officer of Zai Lab Ltd. The filing details the acquisition of 920 American Depositary Shares (ADSs) upon vesting of Restricted Share Units (RSUs) and the disposal of 315 ADSs withheld to cover taxes, resulting in a total beneficial ownership of 36,240 direct ADSs. Each ADS represents ten ordinary shares of Zai Lab Ltd.
- Published
- 05 Oct 2026 21:02
- News subject
- Deals and strategy
- Why this score
- No clear directional signal in the available text
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 9.0d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
EarningsFinanceLife Sciences
—Unscored
Market updateNot used in direction
Is Zai Lab (ZLAB) Cheap After Its ESMO 2026 Lung Cancer Data Update?
ESMO data disclosure puts Zai Lab's early lung cancer program in focus Zai Lab (ZLAB) has put fresh attention on its pipeline after confirming that global Phase 1b/1c data for zocilurtatug pelitecan in extensive-stage small cell lung cancer will appear at the ESMO Congress 2026. The ESMO …
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
ESMO data disclosure puts Zai Lab's early lung cancer program in focus Zai Lab (ZLAB) has put fresh attention on its pipeline after confirming that global Phase 1b/1c data for zocilurtatug pelitecan in extensive-stage small cell lung cancer will appear at the ESMO Congress 2026. The ESMO update lands after a mixed period for Zai Lab, with the share price down 7.24% over the past 30 days, yet up 27.52% on a 90 day basis and 40.39% year to date, while the 1 year total shareholder return is still down 27.91%, signaling recent momentum building off a weaker long term base. Surf 19 high quality und
- Published
- 04 Oct 2026 03:09
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 10.8d old
- Text assessed
- Available headline and article text
- Duplicates
- 3 consolidated
Balance SheetClinical TrialsFuture Cash FlowsOncologyShare PriceShareholder
—Unscored
Market updateNot used in direction
Zai Lab (ZLAB) Puts Zoci Data In Focus Following ESMO Reveal As Valuation Debate Builds
Zai Lab (ZLAB) is drawing attention to its oncology pipeline, particularly with the upcoming global data readout for zoci in extensive-stage small cell lung cancer at the 2026 ESMO Congress. Despite recent stock fluctuations, a valuation debate is building around the company, with some an…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Zai Lab (ZLAB) is drawing attention to its oncology pipeline, particularly with the upcoming global data readout for zoci in extensive-stage small cell lung cancer at the 2026 ESMO Congress. Despite recent stock fluctuations, a valuation debate is building around the company, with some analyses suggesting ZLAB is undervalued against a fair value of $33.30, while others, using a P/S lens, show mixed messages. The company's growing portfolio and fresh clinical catalysts are factors in this discussion about its current share price of US$24.33.
- Published
- 03 Oct 2026 10:24
- News subject
- Market update
- Why this score
- Positive valuation view
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 11.5d old
- Text assessed
- Stored article
- Duplicates
- 3 consolidated
EarningsFinancial MarketsLife Sciences
—Unscored
Market updateNot used in direction
Clinical Trial Data Reveal Could Be A Game Changer For Zai Lab (ZLAB)
Zai Lab (ZLAB) is set to present Phase 1b/1c data for its DLL3-targeting ADC zocilurtatug pelitecan at the ESMO Congress on October 26, which could significantly impact its investment narrative. This data release is crucial for demonstrating the company's ability to develop differentiated…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Zai Lab (ZLAB) is set to present Phase 1b/1c data for its DLL3-targeting ADC zocilurtatug pelitecan at the ESMO Congress on October 26, which could significantly impact its investment narrative. This data release is crucial for demonstrating the company's ability to develop differentiated oncology assets beyond its in-licensed portfolio, with analysts forecasting substantial revenue and earnings growth by 2029. The market's reaction to this clinical data will be a key test for Zai Lab's execution on its multi-asset strategy and its path toward profitability.
- Published
- 01 Oct 2026 04:59
- News subject
- Market update
- Why this score
- Operating growth
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 13.7d old
- Text assessed
- Available headline and article text
- Duplicates
- 2 consolidated
EarningsFinancial MarketsLife Sciences
—Unscored
EarningsNot used in direction
Zai Lab stock trades without a verified September catalyst
This article clarifies that Zai Lab stock (ZLAB) remains tied to its Nasdaq listing and operating results, distinguishing it from Z.AI Co Ltd (2513), a separate AI company. It emphasizes that Zai Lab's valuation should be based on its revenue growth, product launches, and clinical pipelin…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
This article clarifies that Zai Lab stock (ZLAB) remains tied to its Nasdaq listing and operating results, distinguishing it from Z.AI Co Ltd (2513), a separate AI company. It emphasizes that Zai Lab's valuation should be based on its revenue growth, product launches, and clinical pipeline, not on unrelated market activities of other companies. The Nasdaq listing and USD as the reference currency are confirmed for Zai Lab Limited.
- Published
- 23 Sep 2026 11:25
- News subject
- Earnings
- Why this score
- Operating growth
- Company focus
- Company discussed · 86%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 21.4d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
EarningsFinanceFinancial MarketsLife Sciences
—Unscored
Analyst actionNot used in direction
Zai Lab Ltd (1ZLB) Receives a Buy from UBS
UBS has reiterated a "Buy" rating on Zai Lab Ltd (1ZLB) with a price target of HK$27.00. The company's shares closed at HK$19.04, and the analyst consensus for Zai Lab Ltd is a "Strong Buy" with a target of €2.74. The article also notes the company's market cap and P/E ratio.
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
UBS has reiterated a "Buy" rating on Zai Lab Ltd (1ZLB) with a price target of HK$27.00. The company's shares closed at HK$19.04, and the analyst consensus for Zai Lab Ltd is a "Strong Buy" with a target of €2.74. The article also notes the company's market cap and P/E ratio.
- Published
- 19 Sep 2026 11:25
- News subject
- Analyst action
- Why this score
- Positive financial language
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 25.4d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
EarningsFinancial MarketsLife Sciences
Earlier company news
ZLAB news archive
Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.
Older news is kept in the archive
There are 54 older ZLAB headlines. Open one page at a time when you need them.
Open older archiveProvider matches checked
Provider mentions not used in the score
A news provider linked these stories to ZLAB, but the headline and available text are not mainly about Zai Lab Ltd. They are kept here for transparency and do not affect the score, confidence, history or wider market totals.
Provider mentions are kept separate
Open the list to see which provider matches were checked and left out of ZLAB sentiment.
Open provider mentionsHow the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme. This is a rule-based evidence measure, not a calibrated probability.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
It measures news already published. It is not a forecast, recommendation or price target.